In Massachusetts, InVivo Therapeutics Holdings Corp., a biomaterials and biomedicals company focused on spinal cord injuries, hired Christopher McNulty as CFO as of March 29th. McNulty was a former SVP of Business Development and Investor Relations at InVivo and worked directly on a follow-on offering and direct financing projects. Prior to InVivo, he worked at Repligen leading its acquisition of Novozymes Sweden, and seemingly is a jack of all trades with degrees in electrical engineering and computer science from MIT as well as an MBA from Harvard. Melanie Morel-Ferris has been serving as the interim CFO and will stay on as Senior Director of Finance and Controller.
Latest article
Fit for a King: Withdrawn British banknotes converted into furniture
In the United Kingdom, designer Saskia Boersma, the Surface Matter collective, and the material studio Plasticiet have transformed £2.5 million (US$3.5 million) worth of withdrawn British banknotes...
Under Armour and UNLESS launch three plant-based sneakers
In Milan, popular athleisure brand Under Armour has partnered with UNLESS, a company known for producing completely renewable garments, to market three completely plant-based...
Solar Foods creates mayonnaise (mostly) from thin air
In Finland, Solar Foods has filed a patent application for a mayonnaise formulation made using its Solein protein, which is produced by a microbe...